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In this short review, I will focus on how a unique tau gene may produce many tau isoforms 
through alternative splicing and how the phosphorylation of these isoforms by different kinases 
may affect their activity and behaviour. Indeed, each of the different tau isoforms may play a 
distinct role under both physiological and pathological conditions. Thus, I will discuss whether a 
tau code exists that might explain the involvement of different tau isoforms in different cellular 
functions.
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inﬂ  uencing their activity (Avila et al., 2004). In neurodegenerative 
diseases, modiﬁ  cations to tau are important for the development of 
tauopathies (Lee et al., 2001) and the presence of extracellular tau, 
as a consequence of neuron death, could result from its interac-
tion with muscarinic receptors on surrounding neurons, provok-
ing toxicity in those neurons (Gomez-Ramos et al., 2006, 2008). 
Different functional tau isoforms arise through alternative splicing 
and their behaviour can be modiﬁ  ed by different phosphorylation 
events Tau is also subject to ubiquitination, glycation, nitration, 
truncation and other posttranslational modiﬁ  cations that could 
result in the appearance of additional tau isoforms (Avila et al., 
2004). Thus, these different isoforms could fulﬁ  l a different role 
in all of the processes indicated above. Although in this review I 
will focus on those tau isoforms arising from alternative splicing 
or phosphorylation.
TAU GENE, TAU PROTEIN
Tau is a microtubule associated protein found in the brain that 
promotes microtubule polymerisation in vitro (Weingarten et al., 
1975). Tau binds to the carboxy terminal region of tubulin (Serrano 
et al., 1984), the main component of microtubules, through a region 
known as the microtubule-binding domain (Goedert et al., 1989; 
Lee et al., 1988). This region of tau contains three or four (depend-
ing on the speciﬁ  c tau isoform) similar but not identical motifs of 
31 or 32 residues, known as the microtubule binding repeats. Those 
tau isoforms with three repeats are described as 3Rtau, whereas 
those with four repeats are deﬁ  ned as 4Rtau.
The unique human tau gene is located on chromosome 17q21 
(Andreadis et al., 1992; Neve et al., 1986) and it can be transcribed 
into a nuclear RNA with 16 exons that can yield different tau iso-
forms through alternative splicing (Goedert et al., 1989). Six dif-
ferent protein isoforms of tau have been described in the central 
nervous system (CNS), three 3Rtau and three 4Rtau isoforms, the 
fourth microtubule binding repeat reﬂ  ecting the alternative splic-
ing of exon 10.
INTRODUCTION
Biological complexity is not only the consequence of the number of 
genes expressed in an organism but it is also the consequence of fur-
ther modiﬁ  cations to the gene products. Once a gene is transcribed 
into nuclear RNA, this RNA can be modiﬁ  ed by alternative splicing 
to yield distinct mRNAs, which may subsequently be translated 
into different protein isoforms. Post-translational modiﬁ  cation of 
each of these isoforms by phosphorylation (or other processes) can 
affect the behaviour of each isoform, producing a wide variation 
in the activity of the different isoforms generated from an unique 
gene such as tau. It has been suggested that the post-translational 
modiﬁ  cations that direct the diverse protein functions of a protein 
may reﬂ  ect a code and for example, a histone code exists that directs 
the different functions of chromatin (Jenuwein and Allis, 2001; 
Strahl and Allis, 2000).
In this review, I shall look at how a single tau gene can gen-
erate many tau isoforms, ﬁ  rst through alternative RNA splicing 
and afterwards, by different post-translational modiﬁ  cations, 
phosphorylation being the most important. Finally, I will discuss 
whether these modiﬁ  cations could deﬁ  ne a tau code that might 
explain the role of different tau isoforms in distinct cellular func-
tions, or in the different neurodegenerative disorders known as 
tauopathies.
TAU FUNCTION
Tau plays a role in different cellular events and as a microtubule asso-
ciated protein, tau is principally involved in microtubule dynamics, 
stabilizing the microtubule polymers (Drubin and Kirschner, 1986; 
Feinstein and Wilson, 2005; Goode et al., 1997). However, it has also 
been proposed that the tau protein is a key component of axonal 
transport (Dixit et al., 2008; Ebneth et al., 1998; Yuan et al., 2008) 
and more recently, tau was found to bind to and inhibit histone 
deacetylase HDAC6 (Ding and Johnson, 2008; Perez et al., 2009), 
impairing its activity and facilitating tubulin acetylation. In addi-
tion, tau can also bind to other proteins apart from tubulin, perhaps 
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3R AND 4R TAU ISOFORMS
Alternative splicing of exon 10 in tau, results in isoforms that con-
tain either three (3R tau) or four (4R tau) microtubule binding 
repeats. The ratio of Tau 4R to Tau 3R approximates to one in the 
normal brain, both in terms of mRNA and protein, although in 
some tauopathies this ratio is affected and this might be sufﬁ  cient 
to cause neurodegeneration. In Frontotemporal dementia with 
Parkinson’s linked to chromosome 17 (FTDP-17) and corticoba-
sal degeneration (CBD), there is an increase in the 4R tau/3R tau 
ratio, while in Pick’s disease there are no phosphorylated tau iso-
forms containing exon 10 (Buee et al., 2000). Furthermore, 3Rtau 
is preferentially expressed in myotonic dystrophy type 1 (DM1), 
the main isoforms that are expressed in foetal neurons (Ghanem 
et al., 2009). By contrast, exonic and intronic mutations in tau asso-
ciated with FTDP-17 may result in the forced expression of exon 
10 (Grover et al., 1999; Hutton et al., 1998; Spillantini et al., 1998; 
Varani et al., 1999).
Curiously, some tau mutations present in FTDP-17 patients 
could produce a change in tau phosphorylation. The K257T 
mutation generates a new threonine residue although it remains 
unclear whether or not it may be modiﬁ  ed. Alternatively, the P301S 
mutation results in the appearance of a serine (underlined) in the 
sequence VSGGGS, generating a SXXXS motif needed for GSK3 
phosphorylation. Finally, the S320Y mutation prevents the phos-
phorylation of a serine that can be phosphorylated by PKA or by 
MAR kinase in vitro (Schneider et al., 1999).
TAU KINASES AND PHOSPHATASES
The putative enzymes that could participate in establishing a tau 
code are the kinases and phosphatases that act on tau. There are 45 
serine, 35 threonine and 5 tyrosine residues that can be phospho-
rylated in the longest CNS tau isoform of 441 residues (Goedert 
et al., 1989). In the most prevalent tauopathy, Alzheimer’s disease 
(AD), 40 phosphorylation sites have been reported (Hanger et al., 
2009; Wang and Liu, 2008), two of which are tyrosine residues 
(Lee et al., 2004; Noble, 2004) and the rest are either serine or 
threonine residues. These serine and threonine residues can be 
classiﬁ  ed into two groups: those that can be modiﬁ  ed by proline 
directed kinases like GSK3, cdk5, p38MAP kinase or JNK; and 
those that can be phosphorylated by non-proline directed kinases 
like PKA, MAR(PAR-1) kinase, CKII, PKC or calcium-calmodu-
lin kinase (Avila et al., 2004). Among all of these kinases, GSK3 is 
that which can modify most sites in the tau molecule, although 
in some cases GSK3 modiﬁ  cation requires prior phosphorylation 
of tau by another kinase (Cho and Johnson, 2003). On the other 
hand, several tau phosphatases have been described such as PP1, 
PP2A and PP2B (Gong et al., 1994a,b), of which PP2A is capable of 
dephosphorylating most phosphorylated sites in the tau molecule 
(Goedert et al., 1995; Gong et al., 2000).
Tau phosphorylation is developmentally regulated, and it is 
more prevalent in foetal neurons and less intense in adult neu-
rons (Morishima-Kawashima et al., 1995). Moreover, different 
tau isoforms may be phosphorylated at different sites (Hernandez 
et al., 2003), which could be the origin of the tau code. In addition, 
tau phosphorylation may facilitate the binding of the protein to 
other proteins that might regulate its activity, for example tau 
binding to Pin-1, a chaperone of phosphorylated proteins, (Lu 
et al., 1999).
The activity of kinases on tau may also be modulated by differ-
ent mechanisms, for example beta amyloid peptide can regulate 
GSK3 activity through the insulin and wnt signalling pathways 
(Barth et al., 1997). Moreover, extracellular matrix components, 
like laminin, can also regulate Akt/GSK3 signalling (Chen et al., 
2009). In addition, p73 (a member of the p53 family) modulates 
JNK activity to regulate tau phosphorylation (Wetzel et al., 2008), 
while cdk5 may increase its activity after an intracellular increase 
of calcium (Patrick et al., 1999).
THE EFFECT OF TAU PHOSPHORYLATION ON ITS ACTIVITY
All the previously indicated functions of tau can be regulated 
by phosphorylation, and since phosphorylation at different 
sites could have different consequences for each of these func-
tions, a tau code could exist. For example, tau can interact with 
the neuronal plasma membrane through the amino terminal 
region of the protein and phosphorylation of that region could 
prevent such interactions (Arrasate et al., 2000; Brandt et al., 
1995). The interaction of tau with microtubules is also regu-
lated by phosphorylation whereby phosphorylation generally 
reduces the afﬁ  nity of tau for microtubules (Avila et al., 2004), 
although some exceptions have been reported (Schneider et al., 
1999). Phosphorylation of the microtubule binding region (resi-
dues 244-368 of the tau molecule), mainly at serine 262 and 356, 
decreases the interaction of tau with microtubules (Buee et al., 
2000). Moreover, phosphorylation in the regions adjacent to the 
microtubule binding domain may decrease the interaction of 
the tau protein with microtubules, for example phosphorylation 
at serine 214 or threonine 231. This phosphothreonine is the 
binding site for Pin-1, a chaperone that facilitates dephospho-
rylation of tau at that site by the PP2A phosphatase (Lu et al., 
1999). Phosphorylation of tau regulates its axonal transport 
(Cuchillo-Ibanez et al., 2008), as well as facilitating its interac-
tion with other proteins that could regulate some of its activities, 
like 14-3-3 (Sadik et al., 2009). In addition, the reported inter-
action of tau with muscarinic receptors appears to be regulated 
(decreased) by phosphorylation, probably at the C-terminal of 
tau (ser 396-404) (Gómez-Ramos, A. et al. unpublished). Finally, 
phosphorylation at residues 396/404 of the C-terminal region 
favours the formation of a heterotrimeric complex between phos-
photau, α-synuclein and GSK3β (Duka et al., 2009).
Tau is also known to form self aggregates and this process is 
also modulated by phosphorylation (Santa-Maria et al., 2004). 
Soluble hyperphosphorylated tau (p-tau), associated with AD, can 
sequester normal tau, MAP1 and MAP2, causing the inhibition 
of microtubule assembly and the disassembly of already formed 
microtubules (Alonso et al., 1997). It was suggested that P-tau but 
not unmodiﬁ  ed tau can interact with MAPs, although the nature 
of the phosphorylated residues involved in this interaction remains 
unclear. In AD, another post-translational modiﬁ  cation of tau could 
also be regulated by phosphorylation, its truncation (Mondragon-
Rodriguez et al., 2008; Wischik et al., 1997). Thus, phosphorylation 
of residues in different regions of tau produces different effects on 
tau function or dysfunction.Frontiers in Aging Neuroscience  www.frontiersin.org  July  2009 | Volume  1 | Article  1 | 3
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TAU PHOSPHORYLATION IN NEURODEGENERATIVE 
DISORDERS
Up to 40 residues have been seen to be modiﬁ  ed in tau protein 
isolated from the brain of AD patients (Hanger et al., 2009), with 
GSK3 being identiﬁ  ed as the kinase that could phosphorylate 
more sites in the tau molecule (Figure 1). However, tau phos-
phorylation in AD could result from the phosphorylation of dif-
ferent tau isoforms modiﬁ  ed at different sites, rather than the 
modiﬁ  cation of the 40 sites in a single tau molecule (Hernandez 
et al., 2003).
In other tauopathies, like progressive supranuclear palsy (PSP), 
only eight phosphorylation sites have been reported (Wray et al., 
2008), although all of these sites (Ser 46, Thr181, Ser202, Thr217, 
Thr231, Ser235, Ser396 or Ser400, and Thr403 or Ser404) are also 
modiﬁ  ed in AD and they might be modiﬁ  ed by GSK3. It is not 
known whether these differences in the number of  phosphorylated 
FIGURE 1 | Tau phosphorylation in tauopathies. (A) More than 40 residues 
of the different tau isoforms can be modiﬁ  ed in Alzheimer disease (AD). 
Some of these sites are modiﬁ  ed by GSK3, and the modiﬁ  ed serine residues 
(184, 198, 199, 202, 210, 214, 235, 237 , 258, 262, 289, 356, 396, 400, 404, 
409, 412, 413, 416) or threonine residues (69, 175, 181, 212, 217 , 231, 414) 
have been localized within the tau molecule (Hanger et al., 2009). In addition, 
there are three possible tyrosine residues (18, 29, 394) that could be modiﬁ  ed 
in AD, the main candidates each located in the amino terminal domain. Fewer 
residues modiﬁ  ed by GSK3 have been identiﬁ  ed in tau from progressive 
supracellular palsy (PSP). (B) These and other phosphorylation events can 
regulate the interaction of tau protein with the cell membrane, microtubules, 
other proteins or its self association. The circles indicate the localization of the 
phosphorylated residues that prevent interactions (Ser 199-202) with the cell 
membrane, (Ser 262) with microtubules, or (Ser 396-404) with muscarine 
receptors. Also, when the serines (396-404) are phosphorylated the 
interaction of phospho tau with α-synuclein and GSK3β is favoured. 
(C) Scheme showing the six CNS tau isoforms. Three 3R and three 4R tau 
isoforms.)Frontiers in Aging Neuroscience  www.frontiersin.org  July  2009 | Volume  1 | Article  1 | 4
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residues in tauopathies like AD or PSP could provoke the  appearance 
of  different ﬁ  lamentous tau polymers in these conditions (Arrasate 
et al., 1997), in addition to other reported factors that could also 
inﬂ   uence the morphology of these ﬁ  laments  (Arrasate et  al., 
1997).
In AD, paired helical (PHF) and straight (SF) ﬁ  laments can 
be detected in the patients’ brain (Kidd, 1963), whereas mainly 
straight ﬁ   laments are observed in PSP (Perez et  al., 1998). 
Alternatively, tau can be proteolyzed (truncated) in different 
ways in tauopathies like AD or PSP, and truncated tau can be 
phosphorylated by kinases like GSK3 (Rissman et al., 2004) and 
indeed, it has been suggested that tau cleavage may precede its 
hyperphosphorylation (Cribbs et al., 2004). In AD, tau fragments 
of different sizes have been described that lack C-terminal resi-
dues (up to 17 kDa) (Binder et al., 2005; Gamblin et al., 2003; 
Park and Ferreira, 2005). However, in PSP (Wray et al., 2008) a 
35 kDa tau fragments lacking the N-Terminal region has been 
identiﬁ  ed. Curiously, this tau fragment is less   evident in the CSF 
of PSP patients (Borroni et al., 2008), perhaps because it forms 
aggregates that are not secreted into the CSF. On the other hand, 
tau truncated at asp 421 is toxic since it induces mitochondrial 
fragmentation and elevated oxidative stress, which could in turn 
result in neuron death (Quintanilla et al., 2009).
In summary, many tau protein isoforms can be generated from 
a single tau gene and some of these isoforms may undergo different 
modiﬁ  cations, such as phosphorylation. These differences in phos-
phorylation could reﬂ  ect a tau code that could explain the different 
activities fulﬁ  lled by tau (Figure 1B). Indeed, phosphorylation of 
the N-terminal half of the tau molecule could affect its interaction 
with the cell membrane, while phosphorylation in the microtubule 
binding domain and its adjacent regions will impair the interaction 
of tau with microtubules, as well as inﬂ  uencing tau-tau self assem-
bly. By contrast, phosphorylation at the C-terminal region affects 
the interaction of tau with other proteins, like muscarinic receptors, 
or the formation of the α-synuclein-GSK3β-tau complex.
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